The three main stumbling blocks for anticancer T cells

Trends in Immunology

Volumn 33, Issue 7, 2012, Pages 364-372

  Baitsch, Lukas ^a,b   Fuertes Marraco, Silvia A ^a   Legat, Amandine ^a   Meyer, Christiane ^a   Speiser, Daniel E ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Coreceptors; Immune suppression; Immunotherapy; Self tolerance; Tumor immunity

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CD38 ANTIGEN; CD94 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 7; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; STRESS ACTIVATED PROTEIN KINASE; SUPPRESSOR OF CYTOKINE SIGNALING 3; T LYMPHOCYTE RECEPTOR;

ACTIVE IMMUNIZATION; ANTIGEN PRESENTING CELL; APOPTOSIS; AUTOIMMUNITY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL SURVIVAL; CELL TRANSFER; CYTOKINE PRODUCTION; EFFECTOR CELL; GENE EXPRESSION PROFILING; HUMAN; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; INTERFERON PRODUCTION; INTRACELLULAR SIGNALING; LEUKEMIA CELL LINE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY T LYMPHOCYTE; METASTASIS; NONHUMAN; PROTEIN PHOSPHORYLATION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION;

ANIMALS; AUTOIMMUNITY; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84862682110     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2012.02.006     Document Type: Review

References (107)

1. Galluzzi L., et al. Trial watch: monoclonal antibodies in cancer therapy. Oncoimmunology 2012, 1:28-37.
2. Kantoff P.W., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010, 363:411-422.
3. Yuan J., et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:16723-16728.
4. Fourcade J., et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 2010, 207:2175-2186.
5. Baitsch L., et al. Exhaustion of tumor-specific CD8 T cells in metastases from melanoma patients. J. Clin. Invest. 2011, 121:2350-2360.
6. Wherry E.J. T cell exhaustion. Nat. Immunol. 2011, 12:492-499.
7. Walker L.S., Sansom D.M. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat. Rev. Immunol. 2011, 11:852-863.
8. Karwacz K., et al. PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol. Med. 2011, 3:581-592.
9. Wang S.F., et al. Early T cell signalling is reversibly altered in PD-1 T lymphocytes infiltrating human tumors. PLoS ONE 2011, 6:e17621.
10. Hinrichs C.S., et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 2011, 117:808-814.
11. Sallusto F., et al. From vaccines to memory and back. Immunity 2010, 33:451-463.
12. Ji Y., et al. Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nat. Immunol. 2011, 12:1230-1237.
13. Gattinoni L., et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 2011, 17:1290-1297.
14. Redmond W.L., Sherman L.A. Peripheral tolerance of CD8 T lymphocytes. Immunity 2005, 22:275-284.
15. Cole D.K., et al. Human TCR-binding affinity is governed by MHC class restriction. J. Immunol. 2007, 178:5727-5734.
16. Schmid D.A., et al. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J. Immunol. 2010, 184:4936-4946.
17. Colonna M., Cella M. Crosspresentation: plasmacytoid dendritic cells are in the business. Immunity 2007, 27:419-421.
18. Baumgaertner P., et al. Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells. Int. J. Cancer 2011, 10.1002/ijc.26297.
19. Zippelius A., et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 2004, 64:2865-2873.
20. Ahmadzadeh M., et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009, 114:1537-1544.
21. Chappert P., Schwartz R.H. Induction of T cell anergy: integration of environmental cues and infectious tolerance. Curr. Opin. Immunol. 2010, 22:552-559.
22. Choi S., Schwartz R.H. Molecular mechanisms for adaptive tolerance and other T cell anergy models. Semin. Immunol. 2007, 19:140-152.
23. Wells A.D. New insights into the molecular basis of T cell anergy: anergy factors, avoidance sensors, and epigenetic imprinting. J. Immunol. 2009, 182:7331-7341.
24. Han S., et al. Role of antigen persistence and dose for CD4+ T-cell exhaustion and recovery. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:20453-20458.
25. Shin H., et al. Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection. J. Exp. Med. 2007, 204:941-949.
26. Mueller S.N., Ahmed R. High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:8623-8628.
27. Wherry E.J., et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007, 27:670-684.
28. Crawford A., Wherry E.J. The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses. Curr. Opin. Immunol. 2009, 21:179-186.
29. Riley J.L. PD-1 signaling in primary T cells. Immunol. Rev. 2009, 229:114-125.
30. Haining W.N., et al. Identification of an evolutionarily conserved transcriptional signature of CD8 memory differentiation that is shared by T and B cells. J. Immunol. 2008, 181:1859-1868.
31. Quigley M., et al. Transcriptional analysis of HIV-specific CD8(+) T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat. Med. 2010, 16:1147-1151.
32. Shin H., et al. A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection. Immunity 2009, 31:309-320.
33. Agnellini P., et al. Impaired NFAT nuclear translocation results in split exhaustion of virus-specific CD8+ T cell functions during chronic viral infection. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:4565-4570.
34. Kumar R.K., Penny R. Escape of tumours from immunological destruction. Pathology (Phila.) 1982, 14:173-179.
35. Ye X., et al. Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:3916-3920.
36. Willimsky G., et al. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J. Exp. Med. 2008, 205:1687-1700.
37. Nguyen L.T., et al. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J. Exp. Med. 2002, 195:423-435.
38. Kim P.S., Ahmed R. Features of responding T cells in cancer and chronic infection. Curr. Opin. Immunol. 2010, 22:223-230.
39. Appay V., et al. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J. Immunol. 2006, 177:1670-1678.
40. Oved K., et al. Predicting and controlling the reactivity of immune cell populations against cancer. Mol. Syst. Biol. 2009, 5:265.
41. Radoja S., et al. CD8(+) tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis. J. Immunol. 2001, 167:5042-5051.
42. Jeon M.S., et al. Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity 2004, 21:167-177.
43. Monu N., Frey A.B. Suppression of proximal T cell receptor signaling and lytic function in CD8+ tumor-infiltrating T cells. Cancer Res. 2007, 67:11447-11454.
44. Blank U., et al. Inhibitory ITAMs as novel regulators of immunity. Immunol. Rev. 2009, 232:59-71.
45. Vazquez-Cintron E.J., et al. Tumor-induced disruption of proximal TCR-mediated signal transduction in tumor-infiltrating CD8+ lymphocytes inactivates antitumor effector phase. J. Immunol. 2010, 185:7133-7140.
46. Villarino A.V., et al. Posttranscriptional silencing of effector cytokine mRNA underlies the anergic phenotype of self-reactive T cells. Immunity 2011, 34:50-60.
47. Lee P.P., et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 1999, 5:677-685.
48. Beyer M., et al. Cancer vaccine enhanced, non-tumor-reactive CD8(+) T cells exhibit a distinct molecular program associated with " division arrest anergy" . Cancer Res. 2009, 69:4346-4354.
49. Barbey C., et al. IL-12 controls cytotoxicity of a novel subset of self-antigen-specific human CD28+ cytolytic T cells. J. Immunol. 2007, 178:3566-3574.
50. Baitsch L., et al. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS ONE 2011, 7:e30852.
51. Youngblood B., et al. Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity 2011, 35:400-412.
52. Labarriere N., et al. PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting. Cancer Immunol. Immunother. 2008, 57:185-195.
53. Palmer D.C., Restifo N.P. Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol. 2009, 30:592-602.
54. Pellegrini M., et al. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat. Med. 2009, 15:528-536.
55. Barber D.L., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
56. Blackburn S.D., et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 2009, 10:29-37.
57. Matsuzaki J., et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:7875-7880.
58. Nakamoto N., et al. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog. 2009, 5:e1000313.
59. Curran M.A., et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:4275-4280.
60. Zelinskyy G., et al. Virus-specific CD8+ T cells upregulate programmed death-1 expression during acute friend retrovirus infection but are highly cytotoxic and control virus replication. J. Immunol. 2011, 187:3730-3737.
61. Sakuishi K., et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 2010, 207:2187-2194.
62. Jin H.T., et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:14733-14738.
63. Sakuishi K., et al. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol. 2011, 32:345-349.
64. Rosenberg S.A. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat. Rev. Clin. Oncol. 2011, 8:577-585.
65. Porter D.L., et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 2011, 365:725-733.
66. Bendle G.M., et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med. 2010, 16:565-570. 561p following 570.
67. Ochi T., et al. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety. Blood 2011, 118:1495-1503.
68. Linnemann C., et al. T-cell receptor gene therapy: critical parameters for clinical success. J. Invest. Dermatol. 2011, 131:1806-1816.
69. Thomas S., et al. Molecular immunology lessons from therapeutic T-cell receptor gene transfer. Immunology 2010, 129:170-177.
70. Di Stasi A., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 2011, 365:1673-1683.
71. Offringa R. Antigen choice in adoptive T-cell therapy of cancer. Curr. Opin. Immunol. 2009, 21:190-199.
72. Seremet T., et al. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy. Cancer J. 2011, 17:325-330.
73. Yang F., Yang X.F. New concepts in tumor antigens: their significance in future immunotherapies for tumors. Cell. Mol. Immunol. 2005, 2:331-341.
74. Chiang C.L., et al. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int. Rev. Immunol. 2011, 30:150-182.
75. Kenter G.G., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 2009, 361:1838-1847.
76. Speiser D.E., et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 2005, 115:739-746.
77. Schwartzentruber D.J., et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 2011, 364:2119-2127.
78. Schuster S.J., et al. Idiotype vaccination as consolidation therapy: time for integration into standard of care for follicular lymphoma?. J. Clin. Oncol. 2011, 29:4845-4846.
79. Apetoh L., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13:1050-1059.
80. Aymeric L., et al. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res. 2010, 70:855-858.
81. Whiteside T.L. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin. Cancer Biol. 2006, 16:3-15.
82. Igney F.H., Krammer P.H. Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer 2002, 2:277-288.
83. Vignali D.A., et al. How regulatory T cells work. Nat. Rev. Immunol. 2008, 8:523-532.
84. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 2004, 4:941-952.
85. Allavena P., Mantovani A. Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin. Exp. Immunol. 2012, 167:195-205.
86. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 2009, 182:4499-4506.
87. Bronte V., Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 2005, 5:641-654.
88. Shields J.D., et al. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 2010, 328:749-752.
89. Ostman A., Augsten M. Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr. Opin. Genet. Dev. 2009, 19:67-73.
90. Jenkins M.K., Schwartz R.H. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 1987, 165:302-319.
91. Mescher M.F., et al. Signals required for programming effector and memory development by CD8+ T cells. Immunol. Rev. 2006, 211:81-92.
92. Redmond W.L., et al. Distinct requirements for deletion versus anergy during CD8 T cell peripheral tolerance in vivo. J. Immunol. 2005, 174:2046-2053.
93. Schietinger A., et al. Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science 2012, 335:723-727.
94. Zajac A.J., et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 1998, 188:2205-2213.
95. Moskophidis D., et al. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993, 362:758-761.
96. Wherry E.J., et al. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 2003, 77:4911-4927.
97. Oxenius A., et al. Comparison of activation versus induction of unresponsiveness of virus-specific CD4+ and CD8+ T cells upon acute versus persistent viral infection. Immunity 1998, 9:449-457.
98. Lee J., et al. Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways. Mol. Cell. Biol. 2011, 31:3963-3974.
99. Butte M.J., et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007, 27:111-122.
100. Cheung T.C., et al. T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment. J. Immunol. 2009, 183:7286-7296.
101. Bengsch B., et al. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog. 2010, 6:e1000947.
102. Zehn D., Bevan M.J. T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity 2006, 25:261-270.
103. Chemnitz J.M., et al. B and T lymphocyte attenuator-mediated signal transduction provides a potent inhibitory signal to primary human CD4 T cells that can be initiated by multiple phosphotyrosine motifs. J. Immunol. 2006, 176:6603-6614.
104. Assarsson E., et al. 2B4/CD48-mediated regulation of lymphocyte activation and function. J. Immunol. 2005, 175:2045-2049.
105. Cai G., et al. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nat. Immunol. 2008, 9:176-185.
106. Francisco L.M., et al. The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 2010, 236:219-242.
107. Henson S.M., et al. KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells. Blood 2009, 113:6619-6628.